If you’re eyeing Pfizer stock and wondering what’s next, you’re definitely not alone. The last few years have been a roller ...

This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around ...

Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows.

Pfizer Inc. is a global biopharmaceutical leader with a diversified product portfolio and significant scale, supported by ...

Pfizer's stock has been struggling for multiple years, and even a low valuation hasn't made it an enticing option for many investors.

Over the past decade, pharmaceutical maker Pfizer ( PFE -0.53%) has severely lagged the market. Dividends reinvested aside, ...

Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth ...

Pfizer Inc. remains attractive with strong fundamentals, cost control, an expanding market, and new drugs. Click here to read ...

After its best day in nearly four years Tuesday, Pfizer stock gave an encore performance. Shares of the drugmaker closed u ...

Pfizer (PFE) concluded the recent trading session at $24.51, signifying a +1.16% move from its prior day's close.

This drop brings the stock's year-to-date decline to almost 45%. A key question now is how MRNA's performance compares to that of its competitors.